![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and safety of xalnesiran with and without an immunomodulator in virologically suppressed participants with chronic hepatitis B (CHB): Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
|
|
|
AASLD 2023 nov 10-14
listen to live session
https://www.aasld.org/the-liver-meeting
Primary endpoint results from the phase 2, randomized, controlled, adaptive, open-label platform study (PIRANGA)
AASLD 2023 nov 10-14
![1201231](../images/120123/120123-1/1201231.gif)
![1201232](../images/120123/120123-1/1201232.gif)
![1201233](../images/120123/120123-1/1201233.gif)
![1201234](../images/120123/120123-1/1201234.gif)
![1201235](../images/120123/120123-1/1201235.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|